Alloplex Biotherapeutics Inc., a Boston-based cellular therapeutics company, announced the appointment of Mr. Paul Sowyrda to its Corporate Board this week. Mr. Sowyrda brings over three decades of invaluable experience in the pharmaceutical and biotech industries to Alloplex. His extensive backgrou...
Category: Corporate
-
August 22, 2024
Alloplex Biotherapeutics Welcomes Seasoned Pharmaceutical Executive to its Corporate Board
-
March 27, 2024
Alloplex set to validate crucial immunotherapy hypothesis and expands corporate structure with advisory panel.
Alloplex Biotherapeutics has identified cancer tumor types responsive to its lead technology platform, SUPLEXA, in a single-agent study.
-
January 10, 2024
Naturally Occurring Immune Cells may push through where CAR T cells fall short, reports Genetic Engineering and Biotechnology News
Genetic Engineering & Biotechnology News recently published a feature story entitled ‘Immune Cell Therapy May Become More Naturalistic'.
-
August 22, 2023
Alloplex seeks strategic partners and investor meetings at LSX Leaders Congress (Boston, September 2023)
SUPLEXA cellular therapy, a highly differentiated therapy with exceptionally broad promise, has demonstrated single-agent activity in end-stage solid cancer patients
Alloplex’s founder and CEO, Dr. Frank Borriello, will be attending the upcoming LSX Leaders Congress in Boston on September 13 and 14 at the Hynes Convention Centre. Alloplex is seeking strategic partners and investors to support a de-risked Phase 2 ready clinical stage cellular therapy opport...
-
December 15, 2022
Alloplex opens third prestigious site for SUPLEXA-101 first-in-class cellular therapy trial in oncology patients
Southern Oncology Clinical Research Unit in Adelaide joins Cancer Research SA, also in Adelaide, and Gallipoli Medical Research Foundation of Brisbane for the Phase 1 trial of Alloplex Biotherapeutics' autologous SUPLEXA cell immunotherapy.
Alloplex Biotherapeutics today announced the opening of the third site in its first-in-human clinical trial of SUPLEXA: Southern Oncology Cancer Research Unit ‘SOCRU’. SUPLEXA therapy is a highly-differentiated, autologous, non-engineered, multi-cellular therapy derived from patient peripheral b...
-
August 1, 2022
Independent Data Safety Monitoring Board agrees to continue enrollment in SUPLEXA first-in-human trial
No safety signals or adverse events were observed in the first cohort of three patients with solid cancer who have completed treatment with Alloplex Biotherapeutics Inc.'s SUPLEXA Therapeutic Cells.
On Friday 29 August, an independent Data Safety Monitoring Board ‘DSMB’ unanimously agreed that the trial of Alloplex Biotherapeutics Inc.’s SUPLEXA Therapeutic Cells should to continue to full enrollment.
-
April 29, 2022
Alloplex Biotherapeutics announces opening of first clinical trial site
Phase 1 trial of autologous SUPLEXA cell immunotherapy, commences in Adelaide South Australia
Alloplex Biotherapeutics announced today the site opening for its first-in-human clinical trial of SUPLEXA. SUPLEXA therapy is a highly-differentiated, autologous, non-engineered, multi-cellular therapy derived, from patient peripheral blood mononuclear cells. This Phase 1 is a first-in-human, open-...
-
March 29, 2022
Alloplex appoints CLL expert Dr. Jennifer Brown to its scientific advisory board
Dr. Brown, the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and the Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts, is internationally known fo...
-
January 17, 2022
Human Research Ethics Committee (HREC) in Australia approves the start of the first SUPLEXA Phase 1 Clinical Trial
Alloplex Biotherapeutics, Inc. (‘Alloplex’) – a private cellular therapeutics company dedicated to developing and commercializing a global first-in-class cellular therapeutic in oncology – today announced that the Human Research Ethics Committee (HREC) in Australia has approved the clinical...
-
December 15, 2021
Hackensack Meridian Health’s Bear’s Den supports company developing novel way to ‘train’ patients’ own white blood cells
Alloplex Biotherapeutic and Hackensack Meridian Health announce equity investment.
Hackensack Meridian Health, New Jersey’s largest and most comprehensive health network, is proud to announce its support of the clinical development of a highly-differentiated immuno-oncology platform by Boston-based Alloplex Biotherapeutics, Inc.
-
December 8, 2021
Alloplex appoints Dr. Andre Goy to its scientific advisory board
Dr. Goy is Physician in Chief of Hackensack Meridian Health Oncology Care Transformation Service; Chairman & Chief Physician Officer of John Theurer Cancer Center (JTCC) at Hackensack University Medical Center; Lydia Pfund Chair for Lymphoma; Academic Chairman Oncology at Hackensack Meridian School...
-
November 1, 2021
Alloplex forms corporate board
Appoints two members: Dr. Sung-Wuk Kim and TaeOh ‘Jared’ Chung.
Alloplex Biotherapeutics Inc. announced the formation of a Corporate Board today: at a pivotal juncture in the organization’s development as it is poised to embark on its first-in-human clinical trial.
-
September 29, 2021
A tribute to Dr. Martin ‘Mac’ Cheever
It is with great sadness that we learned this week that Dr. Mac Cheever died of complications from what was a planned cardiac surgery earlier this year. Mac’s achievements over 40 years at the Fred Hutchinson Cancer Research Center were well known and admired across the immunology community.
-
May 1, 2020
Alloplex Biotherapeutics Announces Addition to its Scientific Advisory Board
Alloplex Biotherapeutics is pleased to announce the addition of Dr. Robin Robinson to our scientific advisory board.